Switch theme
Sign up to access all valuation multiples
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
2020
42
LTM Revenue $2.9M
LTM EBITDA -$68.4M
$629M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
LENZ Therapeutics has a last 12-month revenue (LTM) of $2.9M and a last 12-month EBITDA of -$68.4M.
In the most recent fiscal year, LENZ Therapeutics achieved revenue of n/a and an EBITDA of -$58.6M.
LENZ Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See LENZ Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $2.7M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$68.4M | XXX | -$58.6M | XXX | XXX | XXX |
| EBITDA Margin | -2381% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$70.9M | XXX | -$58.6M | XXX | XXX | XXX |
| EBIT Margin | -2471% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$62.7M | XXX | -$49.8M | XXX | XXX | XXX |
| Net Margin | -2186% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, LENZ Therapeutics's stock price is $29.
LENZ Therapeutics has current market cap of $822M, and EV of $629M.
See LENZ Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $629M | $822M | XXX | XXX | XXX | XXX | $-2.63 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, LENZ Therapeutics has market cap of $822M and EV of $629M.
LENZ Therapeutics's trades at n/a EV/Revenue multiple, and -10.7x EV/EBITDA.
Equity research analysts estimate LENZ Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
LENZ Therapeutics has a P/E ratio of -13.1x.
See valuation multiples for LENZ Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $822M | XXX | $822M | XXX | XXX | XXX |
| EV (current) | $629M | XXX | $629M | XXX | XXX | XXX |
| EV/Revenue | 219.1x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.2x | XXX | -10.7x | XXX | XXX | XXX |
| EV/EBIT | -8.9x | XXX | -10.7x | XXX | XXX | XXX |
| EV/Gross Profit | 235.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.1x | XXX | -16.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -10.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLENZ Therapeutics's last 12 month revenue growth is 742%
LENZ Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
LENZ Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
LENZ Therapeutics's rule of X is -527% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for LENZ Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 742% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2381% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -527% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
LENZ Therapeutics acquired XXX companies to date.
Last acquisition by LENZ Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . LENZ Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was LENZ Therapeutics founded? | LENZ Therapeutics was founded in 2020. |
| Where is LENZ Therapeutics headquartered? | LENZ Therapeutics is headquartered in United States of America. |
| How many employees does LENZ Therapeutics have? | As of today, LENZ Therapeutics has 42 employees. |
| Who is the CEO of LENZ Therapeutics? | LENZ Therapeutics's CEO is Mr. Evert B. Schimmelpennink. |
| Is LENZ Therapeutics publicy listed? | Yes, LENZ Therapeutics is a public company listed on NAS. |
| What is the stock symbol of LENZ Therapeutics? | LENZ Therapeutics trades under LENZ ticker. |
| When did LENZ Therapeutics go public? | LENZ Therapeutics went public in 2024. |
| Who are competitors of LENZ Therapeutics? | Similar companies to LENZ Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of LENZ Therapeutics? | LENZ Therapeutics's current market cap is $822M |
| What is the current revenue of LENZ Therapeutics? | LENZ Therapeutics's last 12 months revenue is $2.9M. |
| What is the current revenue growth of LENZ Therapeutics? | LENZ Therapeutics revenue growth (NTM/LTM) is 742%. |
| What is the current EV/Revenue multiple of LENZ Therapeutics? | Current revenue multiple of LENZ Therapeutics is 219.1x. |
| Is LENZ Therapeutics profitable? | Yes, LENZ Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of LENZ Therapeutics? | LENZ Therapeutics's last 12 months EBITDA is -$68.4M. |
| What is LENZ Therapeutics's EBITDA margin? | LENZ Therapeutics's last 12 months EBITDA margin is -2381%. |
| What is the current EV/EBITDA multiple of LENZ Therapeutics? | Current EBITDA multiple of LENZ Therapeutics is -9.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
